-
Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients
Not Recruiting
More
This study will evaluate the non-inferiority of Stribild® (elvitegravir/cobicistat/
emtricitabine/tenofovir disoproxil fumarate (E/C/F/TDF)) single-tablet regimen (STR) relative
to regimens consisting of a protease inhibitor (PI) boosted with ritonavir (RTV) plus
Truvada® (FTC/TDF) fixed-dose combination in maintaining HIV-1 RNA < 50 copies/mL at Week 48
in virologically suppressed, HIV-1 infected adults. This study will also evaluate the safety,
tolerability, and efficacy of the two regimens through 96 weeks of treatment.
Stanford is currently not accepting patients for this trial.
For more information, please contact Debbie Slamowitz, 7232804.
Stanford Investigators
View full details
-
Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen
Not Recruiting
More
The main purpose of this study was to compare the effects on bones of the following two drug
combinations:
- maraviroc (MVC), emtricitabine (FTC), plus darunavir/ritonavir (DRV/r)
- tenofovir (TDF) plus emtricitabine (FTC) plus darunavir/ritonavir (DRV/r)
Additional study objectives were the following:
- To see how the drug combinations affect the brain and kidneys.
- To see how well the drug combinations lower the HIV viral load.
- To see how safe the drug combinations are, how well people are able to take the study
drug combinations, and how well their immune systems respond to the study drugs.
Stanford is currently not accepting patients for this trial.
For more information, please contact Debbie Slamowitz, RN, BSN, ACRN, (650) 723-2804.
Stanford Investigators
View full details
-
HIV Prevention and Care of Psychological Trauma in Vulnerable Rwandan Youth
Not Recruiting
More
The investigators propose a prospective single arm pilot cohort study of 100 youth (ages
15-25) to evaluate the feasibility of this project. A convenience sample of subjects will be
enrolled on a voluntary basis from those who come to the day care center located in Nyanza, a
district of the Southern province, in Rwanda.
Stanford is currently not accepting patients for this trial.
For more information, please contact Deborah Slamowitz, 7232804.
Lead Sponsor
Stanford Investigators
View full details
-
Safety of and Immune Response to an Investigational HIV-1 Vaccine With or Without Interleukin-12 (IL-12) in HIV-1 Infected Adults
Not Recruiting
More
Therapeutic HIV vaccines are designed to control HIV infection by boosting the body's natural
immune response. There are currently no FDA-approved therapeutic HIV vaccines. This study
will test whether giving an HIV-1 vaccine together with or without interleukin 12 (IL-12) is
safe and effective. This study will also test a new way of giving the vaccine called
electroporation (EP).
Stanford is currently not accepting patients for this trial.
For more information, please contact SPECTRUM, .
Stanford Investigators
View full details
-
A Study to Treat Subjects With Telaprevir, Ribavirin, and Peginterferon Who Are Coinfected With HIV and Hepatitis C Virus (HCV)
Not Recruiting
More
The purpose of this study is to treat human immunodeficiency virus (HIV) and Hepatitis C
Virus (HCV) co-infected subjects with telaprevir, pegylated interferon alfa-2a
(Peg-IFN-alfa-2a), and ribavirin (RBV) to achieve undetectable hepatitis C virus ribonucleic
acid (HCV RNA) 12 weeks after the last planned dose of study drug.
Stanford is currently not accepting patients for this trial.
For more information, please contact Debbie Slamowitz, (650) 723-2804.
Stanford Investigators
View full details
-
High Dose Vitamin D and Calcium for Bone Health in Individuals Initiating HAART
Not Recruiting
More
This study was done with people who were infected with HIV and needed to start treatment for
their HIV disease. The purpose of this study is to see if taking vitamin D and calcium will
help prevent the bone loss that sometimes happens when people start HIV treatment. For this
study, the following HIV treatment (or HAART) were provided in the form of a single tablet
that contains three different drugs: efavirenz/emtricitabine/tenofovir (EFV/FTC/TDF). These
drugs are approved by the FDA to treat HIV infection. The HIV treatment provided is common
for people who are taking HIV drugs for the first time. The risks seen with this HIV
treatment are the same that you would encounter when taking these drugs outside of the study.
The lists of risks of this HIV treatment are included in this document because the drugs are
provided by the study, not because the drugs are being tested. The purpose of the study is
only to look at the impact of high doses of vitamin D and calcium in preventing bone loss.
There are no study objectives related to HIV treatment (EFV/FTC/TDF).
Stanford is currently not accepting patients for this trial.
For more information, please contact Debbie Slamowitz, 650-723-2804.
Stanford Investigators
View full details
-
Stanford Universities: The Stanford HIV Aging Cohort
Not Recruiting
More
A research study to evaluate the effect of aging and HIV on neurocognitive dysfunction
(declining ability to process information), physical frailty and heart disease. HIV-infected
participants whose virus is controlled on antiretroviral medications will be studied to
determine the rates and risk factors of developing these conditions.
Stanford is currently not accepting patients for this trial.
For more information, please contact Debbie Slamowitz, 650-723-2804.
Lead Sponsor
Stanford Investigators
View full details
-
FTC/RPV/TDF on T-Cell Activation, CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir
Not Recruiting
More
This study was done with people who were infected with HIV, but did not show any signs of
having HIV. They were also feeling well without taking HIV medication and had low or
undetectable levels of the virus in the blood. The purpose of this study was to see if taking
HIV medication (antiretroviral therapy [ART]) would reduce immune activation (a signal that
the body is fighting an infection) in people who have HIV, but did not show symptoms. Also
this study helped determine how safe the drug was and how well people reacted to the drug.
For this study, the following antiretroviral therapy (ART) was be provided in the form of a
single tablet that contains three different drugs: emtricitabine/rilpivirine/tenofovir
disoproxil fumarate (FTC/RPV/TDF). These drugs were combined as one tablet which was approved
by the Food and Drug Administration (FDA) as a single pill to treat HIV infection. The HIV
medication provided was one of the recommended treatments for HIV, including people with low
viral loads (how much HIV you have in your body) who were taking HIV drugs for the first
time. The risks seen with this HIV medication were the same that one would encounter when
taking these drugs outside of the study.
Stanford is currently not accepting patients for this trial.
For more information, please contact Debbie Slamowitz, 650 723-2804.
Stanford Investigators
View full details
-
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Not Recruiting
More
The study will assess if use of maraviroc along with an optimized background regimen of
antiretroviral drugs in usual clinical practice is as safe as using only an optimized regimen
of antiretroviral drugs.
Stanford is currently not accepting patients for this trial.
For more information, please contact Debbie Slamowitz, (650) 723-2808.
Stanford Investigators
View full details
-
Study to Evaluate the Safety and Efficacy of a Single Tablet Regimen of Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Compared With a Single Tablet Regimen of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults
Not Recruiting
More
The purpose of the study was to evaluate the safety and efficacy of the emtricitabine
(FTC)/rilpivirine (RPV)/tenofovir disoproxil fumarate (TDF) single-tablet regimen (STR)
compared with the efavirenz (EFV)/FTC/TDF STR in HIV-1 infected adults who had not previously
received treatment with antiretroviral medications.
Participants were randomized in a 1:1 ratio to receive one of the study treatments.
Randomization was stratified by HIV-1 RNA level (≤ 100,000 copies/mL or > 100,000 copies/mL)
at screening. A treatment duration of 96 weeks was planned, with the option for subjects in
FTC/RPV/TDF STR arm to receive treatment following the Week 96 visit until FTC/RPV/TDF STR is
commercially available or until Gilead Sciences elects to terminate development in that
country.
Stanford is currently not accepting patients for this trial.
For more information, please contact Debbie Slamowitz, (650) 723-2804.
Stanford Investigators
View full details
-
D/C/F/TAF Versus COBI-boosted DRV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment Naive Adults
Not Recruiting
More
This study is to evaluate the safety and efficacy
darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) fixed dose combination
(FDC) tablet versus darunavir (DRV)+cobicistat (COBI)+emtricitabine (FTC)/tenofovir
disoproxil fumarate (TDF) in HIV-1 infected, antiretroviral treatment-naive adults as
determined by the achievement of HIV-1 RNA < 50 copies/mL at Week 24.
Stanford is currently not accepting patients for this trial.
For more information, please contact Debbie Slamowitz, (650) 723-2804.
Stanford Investigators
View full details
-
Safety of EVG+RTV Administered With Other Antiretroviral Agents for the Treatment of HIV-1 Infection
Not Recruiting
More
The main objective of this study is to observe the long-term safety of elvitegravir (EVG)
boosted with ritonavir (RTV) in combination with other antiretroviral (ARV) agents in
participants who have completed a prior EVG+RTV treatment study.
Stanford is currently not accepting patients for this trial.
For more information, please contact Debbie Slamowitz, (650) 723-2804.
Stanford Investigators
View full details
-
Study to Evaluate the Safety and Efficacy of E/C/F/TAF Versus E/C/F/TDF in HIV-1 Positive, Antiretroviral Treatment-Naive Adults
Not Recruiting
More
The primary objective of this study is to evaluate the efficacy of
elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) fixed-dose
combination (FDC) versus elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate
(E/C/F/TDF) in HIV-1 positive, antiretroviral treatment-naive adults.
Stanford is currently not accepting patients for this trial.
For more information, please contact Debbie Slamowitz, 650-723-2804.
Stanford Investigators
View full details
-
Open-label Safety Study of E/C/F/TAF (Genvoya®) in HIV-1 Positive Patients With Mild to Moderate Renal Impairment
Not Recruiting
More
The primary objective of this study is to evaluate the effect of
elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) fixed-dose
combination (FDC) tablet on renal parameters at Week 24 in treatment-naive and
treatment-experienced HIV-positive, adults with mild to moderate renal impairment.
Stanford is currently not accepting patients for this trial.
For more information, please contact Debbie Slamowitz, (650) 723-2804.
Stanford Investigators
View full details
-
Study to Evaluate the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults
Not Recruiting
More
To evaluate the safety and efficacy of Stribild®, a single tablet regimen (STR) containing
fixed doses of elvitegravir (EVG)/cobicistat (COBI [GS-9350])/emtricitabine (FTC)/tenofovir
disoproxil fumarate (TDF) versus efavirenz (EFV)/FTC/TDF (Atripla®) in HIV-1 infected,
antiretroviral treatment-naive adults. Stribild offers an alternative STR for patients who
are not candidates for non-nucleoside reverse transcriptor-based STRs.
Stanford is currently not accepting patients for this trial.
For more information, please contact Debbie Slamowitz, 650-723-2804.
Stanford Investigators
View full details
-
Safety and Efficacy of T Cell Genetic Immunotherapy for HIV
Not Recruiting
More
This study uses autologous (one's own) CD4 T cells modified with a viral vector expressing a
genetic antisense targeting HIV, this vector is called VRX496. Study treatment is by
intravenous infusion of vector modified cells and infusions will be provided every other week
for a total of 4 or 8 doses. These modified cells, once infused, may provide immune support
and are not destroyed by HIV, and thus may delay or reverse HIV disease progression. The
study will enroll up to 40 male and female HIV-positive subjects in up to 8 centers. Subjects
will be 18 years of age and over who have failed or are intolerant to at least one triple
combination of antiretroviral drugs. Subjects must have a viral load between 5,000 and
200,000 copies/ml and a CD4+ count of ≥150, be in good health and have no evidence of active
opportunistic infection, heart disease, or bleeding disorders. Subjects must not be on
corticosteroids, immunomodulating agents or hydroxyurea. Subjects must not have received an
AIDS vaccine or any investigational gene therapy product at any time. Females must not be
pregnant or breastfeeding.
Stanford is currently not accepting patients for this trial.
For more information, please contact Debbie Slamowitz, 650-723-2804.
Stanford Investigators
View full details
-
Study to Evaluate the Safety and Efficacy of Stribild Versus Ritonavir-Boosted Atazanavir Plus Truvada in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults
Not Recruiting
More
To evaluate the safety and efficacy of Stribild®, a single tablet regimen (STR) containing
fixed doses of elvitegravir (EVG)/cobicistat (COBI [GS-9350])/emtricitabine (FTC)/tenofovir
disoproxil fumarate (TDF) versus ritonavir-boosted atazanavir (ATV/r) plus the standard of
care nucleoside reverse transcriptase inhibitor (NRTI) backbone FTC/TDF (Truvada®). ATV/r +
FTC/TDF was selected as the active comparator for this study as it is a preferred protease
inhibitor-based regimen in guidelines for the treatment of HIV-1 infected, antiretroviral
treatment-naive adults.
Stanford is currently not accepting patients for this trial.
For more information, please contact Debbie Slamowitz, 650-723-2804.
Stanford Investigators
View full details
-
Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults
Not Recruiting
More
This study is to evaluate the safety and tolerability of cobicistat-boosted darunavir plus
two fully active nucleoside analogue reverse transcriptase inhibitors in HIV 1 infected,
antiretroviral treatment-naive and treatment-experienced adults with no darunavir (DRV)
resistance-associated mutations.
After the Week 48 Visit, participants will be given the option to participate in an
open-label rollover phase to receive cobicistat and attend visits every 12 weeks until it
becomes commercially available, or until Gilead Sciences elects to terminate development of
cobicistat.
Stanford is currently not accepting patients for this trial.
For more information, please contact Debbie Slamowitz, 650-723-2804.
Stanford Investigators
View full details
-
Quadrivalent HPV Vaccine to Prevent Anal HPV in HIV-infected Men and Women
Not Recruiting
More
Men who have sex with men (MSM) have an increased risk of developing anal human
papillomavirus (HPV) infections, which can be a risk factor for anal cancer. HIV-infected
women are also at risk of anal cancer. This study will evaluate the effectiveness of the Food
and Drug Administration (FDA)-approved quadrivalent HPV vaccine, Gardasil, at preventing anal
HPV infection in HIV-infected MSM and HIV-infected women.
Stanford is currently not accepting patients for this trial.
For more information, please contact Debbie Slamowitz, RN, 650-723-2804.
Stanford Investigators
View full details
-
Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Infected, Antiretroviral Treatment-Naive Adults
Not Recruiting
More
The primary objective of this study is to evaluate the efficacy of
elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (Genvoya®; E/C/F/TAF) fixed-dose
combination (FDC) versus elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate
(Stribild®; E/C/F/TDF) FDC in HIV-1 infected, antiretroviral treatment-naive adults.
Stanford is currently not accepting patients for this trial.
For more information, please contact Debbie Slamowitz, (650) 723-8014.
Stanford Investigators
View full details
-
Investigation of The Effect of Cenicriviroc (CVC) Plus FTC/TDF on Cardiovascular Disease Risk Factors
Not Recruiting
More
This is a single-site substudy, "Investigation of the Effect of Cenicriviroc (CVC) plus
Emtricitabine/Tenofovir (FTC/TDF) on Atherosclerosis Risk Factors", open to all patients
enrolled in the primary study, "A Phase 2b Randomized, Double-Blind, Double-Dummy Trial of
100 or 200 mg Once-Daily Doses of Cenicriviroc (CVC, TBR-652) or Once-Daily EFV, Each With
Open-Label FTC/TDF, in HIV-1-Infected, Antiretroviral Treatment-Naïve, Adult Patients With
Only CCR5-Tropic Virus", in the San Francisco Bay area to evaluate changes in brachial flow
mediated dilation in patients in one of three treatment groups: 1. Cenicriviroc (CVC) at
100mg (2 tablets, 50mg each) QD + CVC matching placebo (2 tablets) QD + Efavirenz (EFV)
matching placebo (1 capsule) QHS + emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) (1
tablet) QD; 2. CVC at 200mg (4 tablets, 50mg each) QD + EFV matching placebo (1 capsule) QHS
+ FTC/TDF (1 tablet) QD; 3. CVC matching placebo (4 tablets) QD + EFV 600 mg (1 capsule) QHS
+ FTC/TDF (1 tablet) QD. The substudy will run for the duration of the primary study. 50
patients of the 150 total enrolled in the primary study will be referred to and enrolled in
the cardiovascular substudy.
Patients enrolled in the substudy and substudy protocol staff will be blinded to study
treatment. Data obtained on this substudy will be analyzed in conjunction with laboratory
data for cardiovascular disease risk factors and HIV-1 RNA levels obtained on the primary
study.
The primary study is a randomized, double-blind, double-dummy, 48-week, comparative study in
approximately 150 HIV-1-infected, treatment-naïve patients with CCR5-tropic virus. Patients
will be stratified by Screening HIV-1 RNA level (≥100,000 copies/mL versus <100,000
copies/mL) and randomized 2:2:1 to one of the three treatment groups. Patients will receive
all medications from the primary study, and thus the primary study site will be responsible
for any adverse outcomes with the drug.
Stanford is currently not accepting patients for this trial.
For more information, please contact Debbie Slamowitz, 6507232804.
Stanford Investigators
View full details
-
Evaluating the Effectiveness of Boceprevir, Pegylated-Interferon Alfa 2b and Ribavirin in Treating Hepatitis C Virus (HCV) Infection in Adults With HIV and HCV Infection
Not Recruiting
More
Hepatitis C virus (HCV) infection is a leading cause of death and illness in people with
HIV-1. At the time the study was designed, the standard treatment for people with HIV-1 and
HCV coinfection included two drugs: pegylated-interferon alfa 2b (PEG-IFN) and ribavirin
(RBV). The purpose of this study was to evaluate the effectiveness of giving boceprevir (BOC)
together with standard treatment in treating HCV infection in people with HIV-1 and HCV
coinfection.
Stanford is currently not accepting patients for this trial.
For more information, please contact Debbie Slamowitz, RN, 650-723-2804.
Stanford Investigators
View full details
-
Consent for Use of Stored Patient Specimens for Future Testing
Not Recruiting
More
The purpose of this study is to obtain informed consent to use stored human biological
materials (HBM) (e.g., blood and other tissues) for future studies that may include genetic
testing.
Stanford is currently not accepting patients for this trial.
For more information, please contact Debbie Slamowitz, 650-723-2804.
Stanford Investigators
View full details
-
Long-Term Data Collection From Participants in Adult AIDS Clinical Trials
Not Recruiting
More
The purpose of this study is to determine what combinations of anti-HIV drugs work best in
patients treated over several years. The study will also assess the occurrence of side
effects and opportunistic infections in patients with low viral loads compared to those with
higher viral loads.
Stanford is currently not accepting patients for this trial.
For more information, please contact Debbie Slamowitz, 650-723-2804.
Stanford Investigators
View full details
